Eddingpharm Co. Ltd., of Hong Kong, and Immutep SA, of Orsay, France, said they started production of Immutep's Immufact IMP321, a LAG-3Ig fusion protein at Wuxi Apptec facilities in China. Wuxi, a contract research organization, initiated process development for the lead product using Immutep's cell line, while Immutep is providing full technical support. Immutep and Eddingpharm will develop the product in combination with first-line chemotherapy in metastatic cancer.